赛诺菲喜保宁功效与作用

(Vigabatrin tablets) is a structural analog of γ-aminobutyric acid (GABA). It inhibits the catabolism of GABA by irreversibly inhibiting GABA transaminase, thereby increasing the concentration of GABA in the brain and achieving anti-epileptic therapeutic effects. In foreign literature, the therapeutic dose of vigabatrin is 0.10 to 0.15 g/(kg·d). It is generally effective 2 weeks after the initial treatment, which is manifested by the reduction or disappearance of convulsive attacks and the disappearance of peak arrhythmia-like EEG.

喜保宁有两个获批的临床适应症，分别是婴儿痉挛症（IS）和难治性复杂部分发作性癫痫（CPS）。与一般癫痫的临床试验不同，在IS的研究中，治疗目标是完全终止癫痫发作（以此定义“反应者”）。 Exploratory studies have shown that treatment with Vigabatrin (50-200 mg/kg/d) can stop attacks in 38% of IS patients. Among them, IS caused by tuberous sclerosis has the best response to Vigabatrin (response rate 87.5%). Symptomatic IS patients with known causes have better curative effects than cryptogenic patients. Subsequent randomized controlled studies showed that Vigabatrin 150 mg/kg/d monotherapy terminated all attacks in 11 patients with tuberous sclerosis IS, and its efficacy was significantly better than hydrocortisone (15 mg/kg/d) as a control (45.4%, 5/11). Patients who were ineffective or intolerant to hormone therapy also had their attacks under control after being transferred to Vigabatrin.

对于难治性CPS，喜保宁也显示了一定的疗效。 Eleven published randomized, double-blind, placebo-controlled clinical studies have shown that the daily dose of Vigabatrin ranged from 1000 mg to 6000 mg, involving a total of 747 patients.喜保宁治疗的患者比安慰剂更容易达到癫痫发作频率降低一半的治疗目标。

从预防到治疗，赛诺菲全方位满足中国的公共健康需求。赛诺菲在心血管/血栓、糖尿病、肿瘤、内科和中枢神经系统等关键的治疗领域拥有领先产品，其中就包括。

Recommended hot articles: /newsDetail/93729.html